Op-ed: Why FTC's decision not to study PBMs is bad for patients, independent pharmacies

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES Why the FTC's recent decision to not study PBMs might hurt consumers and independent pharmacies With its ruling to maintain the status quo, the FTC has decided to take a back-seat and force independent pharmacies to fend for themselves in their on-going fight to secure access to fair prices that allow them to stay in business and continue to serve their local communities and the well-being of their patients.   SPONSORED Join us at ViVE 2022, the industry's new health information technology event! From HLTH ViVE 2022, powered by HLTH and CHIME, will convene top thought leaders who are shaping tech-enabled healthcare and addressing key issues in digital health innovation. Save $150 with code medcity150! Medidata talent acquisition director highlights AI job growth   A tech-enabled solution to drug diversion: What to do when a provider steals a patient's medication By David Brzozowski, Sr. Friday, February 25, 2022 6:52 PM Unfortunately, too many patients go without prescribed medication because healthcare professionals – a distinct minority but no small number – "divert" the drugs for other uses, often abusing the medication themselves. Read more » Healthcare firms were pushed to confront racism. Now some are investing in Black startups. By Blake Farmer, Nashville Public Radio Friday, February 25, 2022 5:38 PM The racial reckoning of the past couple of years has inspired many industries to take a look at their histories and practices. Read more » Why the FTC's recent decision to not study PBMs might hurt consumers and independent pharmacies By David McKay Friday, February 25, 2022 4:48 PM With its ruling to maintain the status quo, the FTC has decided to take a back-seat and force independent pharmacies to fend for themselves in their on-going fight to secure access to fair prices that allow them to stay in business and continue to serve their local communities and the well-being of their patients.   Read more » Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med By Frank Vinluan Friday, February 25, 2022 2:50 PM Neuroscience drug developer Biohaven Pharmaceuticals is expanding its pipeline to include epilepsy and spinal muscular atrophy. The drug developer is acquiring Channel Bioscience and licensing global rights to a Phase 3-ready drug from Bristol Myers Squibb. Read more » 9 Steps to Become Certified in ISO 13485 From MedCity News Knowing the requirements and how to prepare for the ISO 13485 Certification can be hard. Here are 9 steps to stress free preparation. Download this FREE guide to learn more! MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails